Greg Cima
Science and business reporter for 360Dx/GenomeWeb
Articles
-
1 week ago |
360dx.com | Greg Cima
NEW YORK – Agilent Technologies has been making changes to its supply chain, adjusting its pricing, and applying an ongoing restructuring program to mitigate the effects of US tariffs and retaliatory tariffs.
-
1 week ago |
genomeweb.com | Greg Cima
NEW YORK – Researchers from the Johns Hopkins University's Sidney Kimmel Comprehensive Cancer Center reported last week that they have developed a plasma-based fragmentomic test that could help to determine within weeks whether pancreatic cancer patients are responding to treatments including chemotherapies and immunotherapies.
-
2 weeks ago |
360dx.com | Greg Cima
NEW YORK – With new capabilities in digital pathology hardware and its analytical tools, investor enthusiasm in the field is quickly rising, according to industry observers.
-
1 month ago |
360dx.com | Greg Cima
Note: This story has been updated with comments from a conference call to discuss the firm's financial results. NEW YORK – Siemens Healthineers said Wednesday that it expects tariffs implemented by the Trump administration will reduce its second half adjusted earnings before interest and taxes by €200 million ($227 million) to €300 million and its fiscal year adjusted earnings per share by €.15, although the firm posted growth in its Q2 diagnostics business and total revenues.
-
1 month ago |
360dx.com | Greg Cima
Note: This story has been updated with comments from a conference call to discuss the firm's financial results. NEW YORK – Siemens Healthineers said Wednesday that it expects tariffs implemented by the Trump administration will reduce its second half adjusted earnings before interest and taxes by €200 million ($227 million) to €300 million and its fiscal year adjusted earnings per share by €.15, although the firm posted growth in its Q2 diagnostics business and total revenues.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 72
- Tweets
- 149
- DMs Open
- Yes
RT @360DxNews: Meet Ravgen, the Little-Known Company Rattling NIPTs Biggest Players in Court. The firm alleges its competitors infringe its…
RT @360DxNews: UPDATE: FDA Allowed Problematic COVID-19 Tests on the Market Due to Agency's EUA Approach, HHS OIG Finds. In a report releas…
RT @360DxNews: Allergenis Seeks to Change Peanut Allergy Testing. Allergenis claims its assay results are more accurate than other first-li…